At a glance
ClinicalIndex Comparison RecordN/ACompleted· 75 enrolled
Drug / intervention
Peripheral PTA with a drug coated balloondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chansu Vascular Technologies Everolimus-Coated Balloon Percutaneous Transluminal Angioplasty Catheter First-in-Human Clinical Investigation
In Brief
A clinical study evaluating Peripheral PTA with a drug coated balloon for Femoral Artery Stenosis and 3 related conditions. Completed, enrolled 75 participants across 8 sites in 2 countries.
Detailed Summary
The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFemoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
CountriesFrance, Germany
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedFeb 2023
Primary CompletionSep 2023
Study CompletionAug 2025
TodayJul 2026
First PostedFeb 17, 2023
Enrollment StartFeb 17, 2022
Primary CompletionSep 11, 2023
Study CompletionAug 27, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.4 years ago
Interventions
Peripheral PTA with a drug coated balloondevice
Peripheral artery angioplasty